{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:27:00Z","timestamp":1791415620046,"version":"4.3.3"},"reference-count":46,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,2,29]],"date-time":"2016-02-29T00:00:00Z","timestamp":1456704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:p>Nabilone, a synthetic cannabinoid, is approved in many countries including, but not limited to, Canada, the United States, Mexico, and the United Kingdom for the treatment of severe nausea and vomiting associated with chemotherapy. Clinical evidence is emerging for its use in managing pain conditions with different etiologies. We review the efficacy and safety of nabilone for various types of pain as well as its abuse potential, precautions and contraindications, and drug interactions; summarize pertinent clinical practice guidelines; and provide recommendations for dosing, monitoring, and patient education. Citations involving nabilone were identified through systematic reviews evaluating cannabinoids for pain. A systematic search (updated July 23, 2015) of the Ovid MEDLINE, EMBASE, PubMed, and Cochrane Library databases was performed. Eight randomized controlled trials, two prospective cohort trials, and one retrospective chart review were retrieved. Cancer pain, chronic noncancer pain, neuropathic pain, fibromyalgia, and pain associated with spasticity were the pain conditions evaluated. Nabilone was most commonly used as adjunctive therapy and led to small but significant reductions in pain. The most common adverse drug reactions included euphoria, drowsiness, and dizziness. Nabilone was rarely associated with severe adverse drug reactions requiring drug discontinuation, and the likelihood of abuse was thought to be low. Although the optimal role of nabilone in the management of pain is yet to be determined, certain clinical practice guidelines consider nabilone as a third\u2010line agent.<\/jats:p>","DOI":"10.1002\/phar.1709","type":"journal-article","created":{"date-parts":[[2016,2,29]],"date-time":"2016-02-29T01:39:44Z","timestamp":1456709984000},"page":"273-286","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Nabilone for the Management of Pain"],"prefix":"10.1002","volume":"36","author":[{"given":"Corey C.","family":"Tsang","sequence":"first","affiliation":[{"name":"Pharmacy Department The Ottawa Hospital Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirella G.","family":"Giudice","sequence":"additional","affiliation":[{"name":"Pharmacy Department The Ottawa Hospital Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,2,29]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1155\/2001\/469629"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.178.2.107"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20140095"},{"key":"e_1_2_12_5_1","first-page":"165","article-title":"What are the needs of physicians considering medical cannabinoids?","volume":"14","author":"Ware MA","year":"2009","journal-title":"Pain Res Manag"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1187"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2008.00048.x"},{"key":"e_1_2_12_8_1","volume-title":"Palliative care formulary","author":"Twycross R","year":"2011"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.2174\/157015906778019527"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(82)80031-5"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198530020-00002"},{"key":"e_1_2_12_12_1","unstructured":"Nabilone.Micromedex 2.0.Greenwood Village CO:Truven Health Analytics Inc. 2015. Available fromhttp:\/\/micromedex.com\/. Accessed October 5 2014."},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-015-9600-6"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03970.x"},{"key":"e_1_2_12_15_1","unstructured":"Canadian Agency for Drugs and Technologies in Health.Nabilone for chronic pain management: a review of clinical effectiveness safety and guidelines.Ottawa ON:CADTH 2011. Available fromhttp:\/\/www.cadth.ca\/media\/pdf\/htis\/oct-2011\/RC0306-000%20Nabilone%20for%20chronic%20pain.pdf. Accessed October 2 2014."},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39429.619653.80"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/pme.12569"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2012.06.024"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2010.00427.x"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2007.09.002"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0b013e3181c76f70"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2009.12.025"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-006-0218-8"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-006-0611-4"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2006.00085.x"},{"key":"e_1_2_12_26_1","first-page":"119","article-title":"Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring","volume":"6","author":"Maida V","year":"2008","journal-title":"J Support Oncol"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2005.08.001"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2011.11.001"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7303.16"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1155\/2005\/894781"},{"key":"e_1_2_12_31_1","volume-title":"Cesamet (nabilone) product monograph","author":"Valent Canada","year":"2009"},{"key":"e_1_2_12_32_1","unstructured":"Cannabinoid Education (ACE) III Online Program.Mississauga ON:RxMedia Healthcare Communications 2015. Available fromhttp:\/\/vitalcme.com\/program.jsp?program=10031. Accessed October 2 2014."},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02776.x"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/754693"},{"key":"e_1_2_12_35_1","volume-title":"Care beyond cure: management of pain and other symptoms","author":"Neron A","year":"2009"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.130510"},{"key":"e_1_2_12_37_1","unstructured":"The cannabinoid checklist.Montreal QC:Canadian Consortium for the Investigation of Cannabinoids 2015. Available fromhttp:\/\/www.ccic.net\/picture\/upload\/File\/ACE%20Resources\/CCIC%20Physician%20Reference%20Card.pdf. Accessed October 2 2014."},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2013.01.009"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182166ebe"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-S014"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/918216"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.071522"},{"key":"e_1_2_12_43_1","first-page":"109","volume-title":"Guideline for the management of fibromyalgia syndrome pain in adults and children","author":"Buckhardt CS","year":"2005"},{"key":"e_1_2_12_44_1","unstructured":"National Institute for Health and Care Excellence.Neuropathic pain \u2013 pharmacological management. NICE guideline 2013 (CG173)."},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.02999.x"},{"key":"e_1_2_12_46_1","unstructured":"Rapid Response Report.Nabilone for chronic pain: clinical effectiveness safety and guidelines.Ottawa ON:CADTH 2013. Available fromhttp:\/\/www.cadth.ca\/media\/pdf\/htis\/jun-2013\/RA0624%20Nabilone%20for%20Chronic%20Pain%20Final.pdf. Accessed August 8 2015."},{"key":"e_1_2_12_47_1","unstructured":"Nabilone.Lexi\u2010Drugs Online.Hudson OH:Lexi\u2010Comp Inc. 2015. Available fromhttp:\/\/online.lexi.com. Accessed August 8 2015."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1709","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1709","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1709","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:58:29Z","timestamp":1761047909000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,29]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1002\/phar.1709"],"URL":"https:\/\/doi.org\/10.1002\/phar.1709","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,29]]},"assertion":[{"value":"2016-02-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}